Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

OBJECTIVE: To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2 years in patients receiving glucocorticoids. METHODS: This is a 12-month extension of a previously completed 1-year trial of daily ALN, performed to evaluate the effects of ALN over a total of 2 years in 66 men and 142 women continuing to receive at least 7.5 mg of prednisone or equivalent daily. All patients received supplemental calcium and vitamin D. The primary end point was the mean percentage change in lumbar spine bone mineral density (BMD) from baseline to 24 months. Other outcomes included changes in hip and total body BMD, biochemical markers of bone turnover, radiographic joint damage of the hands, and vertebral fracture incidence. RESULTS: The mean (+/-SEM) lumbar spine BMD increased by 2.8 +/- 0.6%, 3.9 +/- 0.7%, and 3.7 +/- 0.6%, respectively, in the groups that received 5 mg, 10 mg, and 2.5/10 mg of ALN daily (P < or = 0.001) and decreased by -0.8 +/- 0.6% in the placebo group (P not significant) over 24 months. In patients receiving any dose of ALN, BMD was increased at the trochanter (P < or = 0.05) and maintained at the femoral neck. Total body BMD was increased in patients receiving 5 or 10 mg ALN (P < or = 0.01). These 2 dose levels of ALN were more effective than placebo at all sites (P < or = 0.05). Bone turnover markers (N-telopeptides of type I collagen and bone-specific alkaline phosphatase) decreased 60% and 25%, respectively, during treatment with ALN (P < or = 0.05). There were fewer patients with new vertebral fractures in the ALN group versus the placebo group (0.7% versus 6.8%; P = 0.026). The safety profile was similar between treatment groups. CONCLUSION: Alendronate is an effective, well-tolerated therapy for the prevention and treatment of glucocorticoid-induced osteoporosis, with sustained treatment advantages for up to 2 years.

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

To determine the effects of long-term daily oral alendronate sodium (ALN) on bone mass in postmenopausal women with osteoporosis, 19 centers enrolled 516 postmenopausal women aged 45-80 years with spine bone mineral density (BMD) at least 2.5 SD below the mean for young premenopausal women in a 3-year, double-blind, placebo-controlled study. Subjects were randomly allocated to one of four treatment groups: placebo; alendronate, 5 or 10 mg/day for 3 years; or alendronate, 20 mg/day for 2 years followed by 5 mg/day for the 3rd year. All patients received 500 mg/day of supplemental calcium to ensure adequate calcium intake. BMD was measured by dual-energy X-ray absorptiometry at several skeletal sites. Nonsignificant mean decreases in BMD of the spine, femoral neck, and trochanter of 0.6, 0.7, and 0.4%, respectively, occurred in the placebo group at 3 years. Relative to placebo-treated patients, spine BMD increased by 5.4%, 7.4%, and 8.4% in the 5, 10, and 20/5 mg ALN groups, respectively. Increases at the femoral neck were 3.5%, 5.5%, and 4.3%, and those at the trochanter were 5.1%, 7.2%, and 7.2%, respectively. Thus, efficacy of 10 and 20/5 mg ALN was similar, whereas the 5 mg dose was less effective. BMD continued to increase over the entire 3-year study duration in the ALN-treated groups and, compared with the other dosage groups, 10 mg ALN produced the largest gains in BMD during the 3rd year. Changes in biochemical markers of bone turnover and mineral homeostasis confirmed the effect of ALN to decrease bone turnover to a new steady-state level. The safety and tolerability of ALN were comparable with those of placebo. In summary, 10 mg daily oral ALN given for 3 years significantly and progressively increases bone mass and is a generally well-tolerated treatment for osteoporosis in postmenopausal women.

Induction of clusterin in acute and chronic oxidative renal disease in the rat and its dissociation from cell injury.

BACKGROUND: Clusterin is a glycoprotein incriminated in diverse biologic processes including complement regulation, cell death, and tissue remodelling. Induction of clusterin occurs in renal and other tissue injuries. EXPERIMENTAL DESIGN: The purpose of this study was to determine the effect of prooxidant states, one acute (glycerol-induced acute renal failure) and the other chronic (vitamin E and selenium deficiency) on renal clusterin expression, and to attempt to delineate the signals which in these in vivo models can elicit expression of clusterin in vitro. RESULTS: In glycerol-induced acute renal failure, a model of rhabdomyolysis, clusterin mRNA was markedly increased 24 hours after injection of glycerol (control 97 +/- 21 versus glycerol 3644 +/- 134 optical density units; p < 0.001). Immunohistochemical clusterin was also increased in glycerol-treated rats with tubules in both cortex and medulla staining for clusterin. In vitamin E and selenium deficiency, clusterin mRNA was increased 9 weeks after initiation of the deficient diet (control 97 +/- 13 versus deficient 1137 +/- 403 optical density units; p < 0.04) as were the number of tubules staining for clusterin. Since renal injury is instigated in the glycerol model by muscle damage, we tested the effect of muscle extract on clusterin expression in vitro. A homogenate of skeletal muscle induced clusterin mRNA and this induction was not associated with disruption of cell membranes and was not inhibited by cycloheximide treatment, but was blocked by actinomycin D. Since increased generation of hydrogen peroxide is a pivotal biochemical lesion in both in vivo models, we tested the effect of peroxide to induce clusterin in vitro; no such induction occurred. CONCLUSIONS: Renal tubular clusterin expression was increased in both acute glycerol-induced renal failure and chronic vitamin E and selenium deficiency, two in vivo models of oxidant injury to the kidney. In vitro induction of clusterin can occur and can be dissociated from cell injury.